Inventor · disambiguated record
Maria Maccecchini
Also filed as: MACCECCHINI MARIA · MACCECCHINI MARIA-LUISA
21 granted patents·18 pending applications·174 citations·filing 1985–2025
94Inventor score
Top patents by PatentIndex Score
39 records- 0189US11596621B2Prevention or treatment of disease states due to metal dis-homeostasis via administration of Posiphen to healthy or sick humansANNOVIS BIO INC·Filed 2020·Granted Mar 7, 2023·2 cites·15 claims
- 0289US2025114330A1(3ar)-1,3a,8-trimethyl-1 ,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegenerationANNOVIS BIO INC·Filed 2024·Application pending·0 cites
- 0387US5523323AUse of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependenceFiled 1993·Granted Jun 4, 1996·88 cites·38 claims
- 0486US11382893B2(3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegenerationANNOVIS BIO INC·Filed 2020·Granted Jul 12, 2022·1 cites·15 claims
- 0582US12390448B2Prevention or of disease states due to metal dis-homeostasis via administration of posiphen to healthy or sick humansANNOVIS BIO INC·Filed 2023·Granted Aug 19, 2025·0 cites·20 claims
- 0682US12144798B2(3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8ahexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegenerationANNOVIS BIO INC·Filed 2022·Granted Nov 19, 2024·0 cites·20 claims
- 0782US2025360104A1Prevention or treatment of disease states due to metal dis-homeostasisANNOVIS BIO INC·Filed 2025·Application pending·0 cites
- 0880US7914810B2Methods for the in situ treatment of bone cancerSYNTHES USA LLC·Filed 2006·Granted Mar 29, 2011·1 cites·10 claims
- 0980US6511963B1Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS functionBEARSDEN BIO INC·Filed 2000·Granted Jan 28, 2003·11 cites·13 claims
- 1080US4599229AMethod of promoting animal growth using antibodies against somatostatinINT MINERALS & CHEM CORP·Filed 1985·Granted Jul 8, 1986·27 cites·10 claims
- 1177US11096926B2(3AR)-1,3A,8-trimethyl-1,2,3,3A,8,8A-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegenerationANNOVIS BIO INC·Filed 2019·Granted Aug 24, 2021·0 cites·18 claims
- 1277US2025025444A1Treatment of neurodegenerative diseases via administration of buntanetap and a phosphodiesterase inhibitorANNOVIS BIO INC·Filed 2024·Application pending·0 cites
- 1374US2025000846A1Methods of treatment or prevention of acute brain or nerve injuriesANNOVIS BIO INC·Filed 2024·Application pending·0 cites
- 1473US11400075B2(3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegenerationANNOVIS BIO INC·Filed 2020·Granted Aug 2, 2022·0 cites·19 claims
- 1573US11376238B2(3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegenerationANNOVIS BIO INC·Filed 2020·Granted Jul 5, 2022·0 cites·19 claims
- 1669US5854217AAllosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS functionBEARSDEN BIO INC·Filed 1995·Granted Dec 29, 1998·20 cites·8 claims
- 1767US5830998AAllosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS functionFiled 1994·Granted Nov 3, 1998·20 cites·7 claims
- 1867US2025235429A1Treatment of diseases via administration of buntanetap and an antidiabetic agentANNOVIS BIO INC·Filed 2024·Application pending·0 cites
- 1967US2025319068A1Treatment of diseases via administration of buntanetap and an antihypertensive agentANNOVIS BIO INC·Filed 2024·Application pending·0 cites
- 2062US2024252467A1Treatment of mental illness via administration of buntanetap and analogues thereofANNOVIS BIO INC·Filed 2024·Application pending·0 cites
- 2161US2018338950A1Prevention or Treatment of Disease States Due to Metal Dis-Homeostasis Via Administration of Posiphen to Healthy or Sick HumansQR PHARMA INC·Filed 2018·Application pending·0 cites
- 2260US9345818B2Methods for the in situ treatment of bone cancerDEPUY SYNTHES PRODUCTS LLC·Filed 2014·Granted May 24, 2016·0 cites·20 claims
- 2359US10383851B2(3aR)-1,3a,8-Trimethyl-1 ,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegenerationQR PHARMA INC·Filed 2017·Granted Aug 20, 2019·0 cites·19 claims
- 2458US12042482B2Methods of treatment or prevention of acute brain or nerve injuriesANNOVIS BIO INC·Filed 2016·Granted Jul 23, 2024·0 cites·7 claims
- 2557US6887867B25H-2,3-benzodiazepine antagonists of excitatory amino acid receptorsTRANSGENOMIC INC·Filed 2001·Granted May 3, 2005·1 cites·12 claims
- 2657US2012225922A1Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing NeurodegenerationMACCECCHINI MARIA·Filed 2011·Application pending·0 cites
- 2757US2015374664A1Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3 b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing NeurodegenerationQR PHARMA·Filed 2015·Application pending·0 cites
- 2857US2011142904A1Methods for the In Situ Treatment of Bone CancerSYNTHES USA LLC·Filed 2011·Application pending·0 cites
- 2956US2014220097A1Method Of Implanting A Sterile, Active Agent-Coated Material And Composition Made According To SameDEPUY SYNTHES PRODUCTS LLC·Filed 2014·Application pending·0 cites
- 3054US2003134799A1Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS functionFiled 2002·Application pending·0 cites
- 3152US2006062825A1Method of implanting a sterile, active agent-coated material and composition made according to sameMACCECCHINI MARIA·Filed 2005·Application pending·0 cites
- 3246US6894048B2Sulfur containing dihydrophthalazine antagonists of excitatory amino acid receptorsTRANSGENOMIC INC·Filed 2003·Granted May 17, 2005·0 cites·18 claims
- 3344US2002188022A1Methods for modulation, stimulation, and inhibition of glutamate reuptakeANNOVIS INC·Filed 2001·Application pending·0 cites
- 3443US6284731B1Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS functionBEARSDEN BIO INC·Filed 1998·Granted Sep 4, 2001·3 cites·6 claims
- 3542US6703390B2Sulfur containing dihydrophthalazine antagonists of excitatory amino acid receptorsTRANSGENOMIC INC·Filed 2001·Granted Mar 9, 2004·0 cites·18 claims
- 3639US2013096316A1Novel Method for Preparation of Bisnorcymerine and Salts ThereofMACCECCHINI MARIA·Filed 2011·Application pending·0 cites
- 3733US6110894AAllosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS functionBEARSDEN BIO INC·Filed 1998·Granted Aug 29, 2000·0 cites·2 claims
- 3833US2002115721A1Esters of alkycarboxy amino acids as prodrugs of modulators of the kainate receptorANNOVIS INC·Filed 2001·Application pending·0 cites
- 3931US2002115688A1Screen for glutamate reuptake inhibitors, stimulators, and modulatorsFiled 2001·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →